DS
Therapeutic Areas
BioMimetix JV Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BMX-001 | High-Grade Glioma | Phase 3 (preparing) |
Leadership Team at BioMimetix JV
JC
James Crapo, MD
CEO
RH
Rob Hellewell
President & Chief Business Officer
SG
Shayne Gad, PhD
VP of Drug Safety, Regulatory Affairs
RO
Robert Ogden, CPA
CFO
SP
Sara Penchev
Director of Clinical Operations
JW
John Wetzel, PhD
Director, Chemistry, Manufacturing and Controls